Xcellerate autologous T cell stimulation therapy: Phase I

The company reported that 6 of 8 treated patients in an ongoing Phase I trial achieved complete remission, with 5 alive an average of >10 months after therapy. A total of 20 patients have been enrolled to date, with enrollment scheduled for completion in the first quarter of 1999. The data were presented at the American Society of Hematology meeting in Miami. ...